Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Total operating expenses for the period under review aggregated to Rs 166.80 crore, up 19.0% YoY.
PBIDT improved by 34.1% to Rs 47.40 crore in Q3 FY26 from Rs 35.34 crore in Q3 FY25.
Profit before tax in Q3 FY26 stood at Rs 31.16 crore, up by 38.9% from Rs 22.44 crore recorded in Q3 FY25.
SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag.
Long term bank facilities (Rs 350.87 crore) - CARE A; Positive (reaffirmed, outlook revised from Stable)
Short term bank facilities (Rs 52.83 crore) - CARE A1 (upgraded from CARE A2+)
SMS Pharmaceuticals announced that the US Food and Drug Administration has approved its associate company VKT Pharma's reformulated Ranitidine tablets in 150mg and 300mg strengths. This approval marks the re-entry of this important acid-reducing medication into the US market after a five-year absence.
The approval by the US FDA comes after extensive safety testing and manufacturing improvements that address previous concerns regarding the formation of NDMA impurity. It is expected to increase patient access to this important medication for patients who rely on it for various health conditions.
According to the company, the approval by the US FDA comes after extensive safety testing and manufacturing improvements that address previous concerns regarding the formation of NDMA impurity. It is expected to increase patient access to this important medication for patients who rely on it for various health conditions.
The company’s consolidated net profit jumped 79.5% to Rs 25.31 crore on 23.2% increase in revenue from operations to Rs 242.43 crore in Q2 FY26 over Q2 FY25.
SVP Global Textiles Ltd, SMS Pharmaceuticals Ltd, Igarashi Motors India Ltd and BIGBLOC Construction Ltd are among the other gainers in the BSE's 'B' group today, 26 November 2025.
Indo US Bio-Tech Ltd surged 19.98% to Rs 132.4 at 12:01 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 2811 shares were traded on the counter so far as against the average daily volumes of 971 shares in the past one month.
SVP Global Textiles Ltd soared 19.83% to Rs 5.68. The stock was the second biggest gainer in 'B' group. On the BSE, 1.33 lakh shares were traded on the counter so far as against the average daily volumes of 33706 shares in the past one month.
SMS Pharmaceuticals Ltd spiked 15.44% to Rs 316.3. The stock was the third biggest gainer in 'B' group. On the BSE, 3.32 lakh shares were traded on the counter so far as against the average daily volumes of 34060 shares in the past one month.
Igarashi Motors India Ltd gained 15.38% to Rs 501.9. The stock was the fourth biggest gainer in 'B' group. On the BSE, 2.74 lakh shares were traded on the counter so far as against the average daily volumes of 2142 shares in the past one month.
BIGBLOC Construction Ltd exploded 14.16% to Rs 65.3. The stock was the fifth biggest gainer in 'B' group. On the BSE, 59903 shares were traded on the counter so far as against the average daily volumes of 9205 shares in the past one month.
Consumer durables shares advanced after declining in the past two trading sessions.
At 14:25 IST, the barometer index, the S&P BSE Sensex advanced 499.45 points or 0.60% to 83,715.73. The Nifty 50 index added 144.80 points or 0.57% to 25,637.10.
In the broader market, the S&P BSE Mid-Cap index rose 0.76% and the S&P BSE Small-Cap index shed 0.21%.
The market breadth was negative. On the BSE, 2,015 shares rose and 2,249 shares fell. A total of 192 shares were unchanged.
Economy:
India’s foreign exchange reserves fell by $5.6 billion to $689.73 billion in the week ended October 31, 2025, the Reserve Bank of India (RBI) said on Friday.
For the week ended October 31, foreign currency assets, a major component of the reserves, decreased by $1.9 billion to $564.59 billion, the RBI data showed.
Value of gold reserves declined by $3.8 billion to $101.72 billion during the week, the RBI said.
The Special Drawing Rights (SDRs) were down by $19 million to $18.64 billion, the apex bank said.
Meanwhile, India's reserve position with the IMF was up by $16.4 million at $4.77 billion in the reporting week, the data showed.
Buzzing Index:
The Nifty consumer durables index advanced 0.52% to 37,812.40. The index declined 2.68% in the past two consecutive trading sessions.
Voltas (up 2%), Crompton Greaves Consumer Electricals (up 1.62%), PG Electroplast (up 1.32%), Blue Star (up 1.24%), Titan Company (up 0.82%), Dixon Technologies (India) (up 0.63%), Havells India (up 0.56%) advanced.
Numbers to Track:
The yield on India's 10-year benchmark federal paper was down 0.28% to 6.503 as compared with previous close 6.521.
In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 88.6975 compared with its close of 88.6500 during the previous trading session.
MCX Gold futures for 5 December 2025 settlement rose 1.79% to Rs 123,240.
The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.09% to 99.51.
The United States 10-year bond yield rose 1.12% to 4.139.
In the commodities market, Brent crude for December 2025 settlement advanced 32 cents or 0.50% to $63.95 a barrel.
Stocks in Spotlight:
Marksans Pharma rose 1.86% after the company announced that it has received zero observations in a current Good Manufacturing Practice (cGMP) inspection conducted by the US Food and Drug Administration (USFDA) at its Goa facility.
SMS Pharmaceuticals rallied 3.24% after the company’s consolidated net profit jumped 79.5% to Rs 25.31 crore on 23.2% increase in revenue from operations to Rs 242.43 crore in Q2 FY26 over Q2 FY25.
Total expenses climbed 17.55% to Rs 209.82 crore in Q2 FY26, compared with Rs 178.50 crore in Q2 FY25. Cost of material consumed stood at Rs 106.56 crore (down 32.88% YoY), manufacturing expenses stood at Rs 25.73 crore (up 17.01% YoY), employee benefit expenses was at Rs 19.25 crore (up 7.42% YoY) and finance cost stood at Rs 5.73 crore (up 24.57% YoY) during the period under review.
On half yearly basis, the company’s consolidated net profit jumped 49.8% to Rs 45.80 crore on 21.4% increase in revenue from operations to Rs 438.48 crore in H1 FY26 over H1 FY25.